BEIJING, China and CAMBRIDGE, Mass., June 01, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that it will present data on its investigational BTK inhibitor zanubrutinib, and host an investor conference call and webcast at the 23rd Congress of the European Hematology Association (EHA). The EHA meeting will take place June 14-17, 2018 in Stockholm, Sweden.
Investor Conference Call & Webcast Information:
| Date and Time: | Friday, June 15, 2018, 8:00 am EDT (Friday, June 15, 2018, 8:00 pm China Standard Time) | |||||||||||||||||||||||||||||||||||||||||
| Dial-In Numbers: | 1-844-461-9930 or 1-478-219-0535 (U.S.), 400-682-8609 or 800-870-0169 (China), 852-30114522 (Hong Kong), 65-66221010 (Singapore), 61-282239773 (Australia), 0856619361 (Stockholm), or 478-219-0535 (International). | |||||||||||||||||||||||||||||||||||||||||
| Conference ID Number: | 7756029 | |||||||||||||||||||||||||||||||||||||||||
| Webcast and Replay: | A live webcast and replay of the event will be available on BeiGene’s investor website, http://ir.beigene.com. The dial-in replay will be available approximately two hours after the conference and will be available for two days following the event. It can be accessed by dialing 1-855-859-2056 (U.S.) or 1-404-537-3406 (International), or 400-683-7185 (China). | |||||||||||||||||||||||||||||||||||||||||
Poster Presentations:
| Title: | Improved Depth of Response with Increased Follow-Up for Patients (PTS) with Waldenström Macroglobulinemia (WM) Treated with Bruton’s Tyrosine Kinase (BTK) Inhibitor Zanubrutinib | |||||||||||||||||||||||||
| Abstract: | PS1186 | |||||||||||||||||||||||||
| Date: | Saturday, June 16, 2018 | |||||||||||||||||||||||||
| Time: | 17:30 - 19:00 (CEST) | |||||||||||||||||||||||||
| Presenter: | Dr. Judith Trotman | |||||||||||||||||||||||||
| Title: | Pooled Analysis of Safety Data from Zanubrutinib (BGB-3111) Monotherapy Studies in Hematologic Malignancies | |||||||||||||||||||||||||
| Abstract: | PF445 | |||||||||||||||||||||||||
| Date: | Friday, June 15, 2018 | |||||||||||||||||||||||||
| Time: | 17:30 – 19:00 (CEST) | |||||||||||||||||||||||||
| Presenter: | Dr. Constantine Tam | |||||||||||||||||||||||||
About Zanubrutinib
Zanubrutinib (BGB-3111) is an investigational small molecule inhibitor of Bruton’s tyrosine kinase (BTK) that is currently being evaluated in a broad pivotal clinical program globally and in China as a monotherapy and in combination with other therapies to treat various lymphomas.
About BeiGene
BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 1,100 employees in China, the United States, and Australia, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin–bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azaciditine) in China under a license from Celgene Corporation.1
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene’s advancement of, and anticipated clinical development and regulatory milestones and plans related to zanubrutinib. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed products and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its technology and drugs; BeiGene's reliance on third parties to conduct drug development, manufacturing and other services; BeiGene’s limited operating history and BeiGene's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.
Investor Contact Media Contact
Lucy Li, Ph.D. Liza Heapes
+1 781-801-1800 +1 857-302-5663
ir@beigene.com media@beigene.com
_________________
1 ABRAXANE®, REVLIMID®, and VIDAZA® are registered trademarks of Celgene Corporation.